OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By USPTO

1.Date of occurrence of the event:2022/12/23
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:
OBI Pharma Inc. was informed by the patent office that patent for OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ has been granted by United States Patent and Trademark Office under the patent number 15/662,162.
OBI-866 is an active immunotherapeutic cancer vaccine targeting SSEA-4, conjugating SSEA-4 and carrier protein KLH and triggers immune responses against hard-to-treat cancers once injected into the human system. OBI-866 has been granted by TFDA to proceed to Phase I human clinical study and is now open for enrollment actively.
7.Any other matters that need to be specified:
New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.